{"meta":{"totalResults":7,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"carboplatin-paclitaxel-bevacizumab regimen"},{"type":"Synonym","name":"carboplatin-Taxol-bevacizumab regimen"},{"type":"Synonym","name":"carbo-Taxol-Avastin regimen"},{"type":"Synonym","name":"carboplatin-paclitaxel-bevacizumab"},{"type":"Synonym","name":"carboplatin-Taxol-bevacizumab"},{"type":"Synonym","name":"carboplatin/paclitaxel/bevacizumab"}],"definition":{"html":"A regimen consisting of bevacizumab, carboplatin and paclitaxel that can be used in the treatment of endometrial, ovarian, fallopian tube and primary peritoneal, vulvar and cervical cancers and non-small cell lung cancer (NSCLC).","text":"A regimen consisting of bevacizumab, carboplatin and paclitaxel that can be used in the treatment of endometrial, ovarian, fallopian tube and primary peritoneal, vulvar and cervical cancers and non-small cell lung cancer (NSCLC)."},"drugInfoSummaryLink":null,"nciConceptId":"C63413","nciConceptName":"Bevacizumab/Carboplatin/Paclitaxel Regimen","termId":657275,"name":"bevacizumab/carboplatin/paclitaxel regimen","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"bevacizumab-carboplatin-paclitaxel-regimen"},{"aliases":[{"type":"CodeName","name":"JM-8"},{"type":"Abbreviation","name":"CBDCA"},{"type":"ForeignBrandName","name":"Carboplat"},{"type":"ObsoleteName","name":"Paraplat"},{"type":"USBrandName","name":"Paraplatin"},{"type":"ForeignBrandName","name":"Paraplatine"},{"type":"ChemicalStructureName","name":"(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum"},{"type":"ChemicalStructureName","name":"1,1-cyclobutanedicarboxylic acid platinum complex"},{"type":"ForeignBrandName","name":"Blastocarb"},{"type":"Synonym","name":"Carboplatin Hexal"},{"type":"Synonym","name":"Carboplatino"},{"type":"ForeignBrandName","name":"Carbosin"},{"type":"ForeignBrandName","name":"Carbosol"},{"type":"ForeignBrandName","name":"Carbotec"},{"type":"ChemicalStructureName","name":"cis-diammine(cyclobutane-1,1-dicarboxylato)platinum"},{"type":"ForeignBrandName","name":"Displata"},{"type":"ForeignBrandName","name":"Ercar"},{"type":"ForeignBrandName","name":"Nealorin"},{"type":"ForeignBrandName","name":"Novoplatinum"},{"type":"ForeignBrandName","name":"Paraplatin AQ"},{"type":"ForeignBrandName","name":"Platinwas"},{"type":"ForeignBrandName","name":"Ribocarbo"},{"type":"ChemicalStructureName","name":"cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)"},{"type":"ChemicalStructureName","name":"cis-diammine(cyclobutanedicarboxylato)platinum II"},{"type":"ChemicalStructureName","name":"platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)"},{"type":"CASRegistryName","name":"41575-94-4"},{"type":"Synonym","name":"carboplatinum"},{"type":"CodeName","name":"JM8"}],"definition":{"html":"A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic.","text":"A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/carboplatin","text":"Carboplatin"},"nciConceptId":"C1282","nciConceptName":"Carboplatin","termId":39176,"name":"carboplatin","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"carboplatin"},{"aliases":[{"type":"Synonym","name":"CEM"},{"type":"Synonym","name":"CEM regimen"}],"definition":{"html":"A regimen containing carboplatin, etoposide and melphalan used for the treatment of childhood neuroblastoma.","text":"A regimen containing carboplatin, etoposide and melphalan used for the treatment of childhood neuroblastoma."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/CEM","text":"CEM"},"nciConceptId":"C125601","nciConceptName":"Carboplatin/Etoposide/Melphalan Regimen","termId":778740,"name":"carboplatin/etoposide/melphalan regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"carboplatin-etoposide-melphalan-regimen"},{"aliases":[{"type":"Synonym","name":"carboplatin-paclitaxel regimen"},{"type":"LexicalVariant","name":"carboplatin-Taxol regimen"},{"type":"Synonym","name":"carbo-Tax regimen"},{"type":"Synonym","name":"CaT regimen"},{"type":"Synonym","name":"PC regimen"},{"type":"Synonym","name":"carboplatin-paclitaxel"},{"type":"Synonym","name":"carboplatin-Taxol"},{"type":"Synonym","name":"carboplatin/paclitaxel"},{"type":"Synonym","name":"paclitaxel-carboplatin"},{"type":"Synonym","name":"paclitaxel-carboplatin regimen"},{"type":"Synonym","name":"paclitaxel/carboplatin"},{"type":"Synonym","name":"paclitaxel/carboplatin regimen"},{"type":"Synonym","name":"TC regimen"}],"definition":{"html":"A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of breast, kidney, cervical, vulvar, endometrial, ovarian, fallopian tube, primary peritoneal, head and neck, including cancer of the nasopharynx, esophageal and esophagogastric junction, and gastric cancers; non-small cell lung cancer (NSCLC); anaplastic carcinoma; anal, small bowel and non-urothelial and urothelial bladder cancer; salivary gland, malignant germ cell and malignant sex cord-stromal tumors; cutaneous and uveal melanoma; squamous cell skin cancer; thymomas and thymic carcinoma; occult primary adenocarcinoma or squamous cell carcinoma. Paclitaxel/carboplatin every 21 days regimen may be used for the treatment of esophageal and esophagogastric junction, and gastric cancers.","text":"A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of breast, kidney, cervical, vulvar, endometrial, ovarian, fallopian tube, primary peritoneal, head and neck, including cancer of the nasopharynx, esophageal and esophagogastric junction, and gastric cancers; non-small cell lung cancer (NSCLC); anaplastic carcinoma; anal, small bowel and non-urothelial and urothelial bladder cancer; salivary gland, malignant germ cell and malignant sex cord-stromal tumors; cutaneous and uveal melanoma; squamous cell skin cancer; thymomas and thymic carcinoma; occult primary adenocarcinoma or squamous cell carcinoma. Paclitaxel/carboplatin every 21 days regimen may be used for the treatment of esophageal and esophagogastric junction, and gastric cancers."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/CARBOPLATIN-TAXOL","text":"CARBOPLATIN-TAXOL"},"nciConceptId":"C63402","nciConceptName":"Carboplatin/Paclitaxel Regimen","termId":657273,"name":"carboplatin/paclitaxel regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"carboplatin-paclitaxel-regimen"},{"aliases":[{"type":"Synonym","name":"carboplatin-etoposide-vincristine regimen"},{"type":"Synonym","name":"carboplatin/etoposide/vincristine regimen"},{"type":"Abbreviation","name":"CEV"},{"type":"Synonym","name":"carboplatin-etoposide-vincristine"},{"type":"Synonym","name":"carboplatin/etoposide/vincristine"}],"definition":{"html":"A regimen containing carboplatin, etoposide, and vincristine which may be used in the treatment of pediatric retinoblastoma (RB).","text":"A regimen containing carboplatin, etoposide, and vincristine which may be used in the treatment of pediatric retinoblastoma (RB)."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/CEV","text":"CEV"},"nciConceptId":"C129579","nciConceptName":"CEV Regimen","termId":784738,"name":"CEV regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cev-regimen"},{"aliases":[{"type":"Synonym","name":"iosfamide-carboplatin-etoposide regimen"},{"type":"Synonym","name":"carboplatin/etoposide/ifosfamide"},{"type":"Abbreviation","name":"CBDCA/IFF/VP-16"},{"type":"Acronym","name":"ICE"},{"type":"Synonym","name":"ifosfamide/carboplatin/etoposide"},{"type":"Synonym","name":"ifosfamide-carboplatin-etoposide regimen"},{"type":"Synonym","name":"ifosfamide/carboplatin/etoposide"}],"definition":{"html":"A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia. Paclitaxel/carboplatin/oral etoposide regimen can be used for the treatment of occult primary adenocarcinoma.","text":"A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia. Paclitaxel/carboplatin/oral etoposide regimen can be used for the treatment of occult primary adenocarcinoma."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/ICE","text":"ICE"},"nciConceptId":"C10345","nciConceptName":"ICE Regimen","termId":631941,"name":"ICE regimen","firstLetter":"i","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"ice-regimen"},{"aliases":[{"type":"Synonym","name":"carboplatin-etoposide-bleomycin regimen"},{"type":"Synonym","name":"JM8-etoposide-bleomycin regimen"},{"type":"Synonym","name":"bleomycin-etoposide-carboplatin regimen"},{"type":"Synonym","name":"JM-8-etoposide-bleomycin regimen"}],"definition":{"html":"A regimen consisting of bleomycin, etoposide and carboplatin used to treat advanced-stage ovarian and testicular germ-cell tumors in children.","text":"A regimen consisting of bleomycin, etoposide and carboplatin used to treat advanced-stage ovarian and testicular germ-cell tumors in children."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/JEB","text":"JEB"},"nciConceptId":"C67289","nciConceptName":"JEB Regimen","termId":657033,"name":"JEB regimen","firstLetter":"j","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"jeb-regimen"}],"links":null}